Tauopathies, including frontotemporal dementia (FTD) and Alzheimer's disease (AD), are neurodegenerative diseases in which tau fibrils accumulate. Recent evidence supports soluble tau species as the major toxic species. How soluble tau accumulates and causes neurodegeneration remains unclear. Here we identify tau acetylation at Lys174 (K174) as an early change in AD brains and a critical determinant in tau homeostasis and toxicity in mice. The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy. The tau-lowering and protective effects of salsalate were diminished in neurons expressing K174Q tau. Targeting tau acetylation could be a new therapeutic strategy against human tauopathies. npg npg
Neurodegenerative tauopathies include brain disorders such as Pick's disease, FTD and progressive supranuclear palsy (primary tauopathies) and secondary tauopathies such as AD 1, 2 . Tauopathies are characterized by neurofibrillary tangles (NFTs) of insoluble hyperphosphorylated tau fibrils. Although accumulation and distribution of NFTs has been used for diagnostic and staging purposes 3 , recent evidence supports a key pathogenic role of soluble tau oligomers 4, 5 . Increased levels of tau oligomers have been detected in the frontal cortex of AD patients at early Braak stages 4, 6 . Injection of recombinant tau oligomers, but not fibrils, impairs memory in non-transgenic mice 7 . In mouse models of tauopathy, levels of tau oligomers correlate with memory loss at various ages 8 . Moreover, suppression of soluble tau improves cognitive function without reducing levels of insoluble NFTs in inducible mouse models of tauopathy 9, 10 .
Both autophagic and proteasomal degradation pathways have been implicated in the tau clearance 11, 12 . In AD brains, tau oligomers appear to be ubiquitinated and to accumulate at synapses, where proteasome components are enriched 13 . Tau undergoes lysine acetylation 14, 15 , which modulates diverse biological processes, including protein stability and protein-protein interactions 16 . Analysis of the soluble fraction of AD brain lysates shows that tau acetylation is enhanced in patients at early and moderate Braak stages, which is consistent with an early role for acetylation in modulating tau accumulation 14 .
Acetylation, but not phosphorylation 17 , regulates aggregation of recombinant tau in vitro 15, 18 . Moreover, inhibition of the deacetylase SIRT1 elevates tau acetylation, suppresses its polyubiquitination and slows its turnover in primary neurons 14 . However, it is unclear which lysine residue(s) are aberrantly acetylated in AD brains and whether they are key determinants of tau homeostasis in vivo.
Here we identify acetylation of tau at K174 (ac-K174) as an early critical pathological change to soluble tau in AD brains using mass spectroscopy and a newly developed antibody specific for ac-tau. We further establish a critical role of K174 in tau homeostasis and toxicity, and we test the effects of the prescription drug salsalate, which inhibits p300-induced tau acetylation, on taumediated behavioral deficits and neurodegeneration in PS19 transgenic mice, an FTD model.
RESULTS
Tau is acetylated at K174 in human AD and tauopathy mice To identify acetylated lysines on soluble tau, we used mild detergents to extract lysates from human AD brains. Tau was immunoprecipitated from soluble AD lysates and subjected to proteolytic digestion and analysis by high-performance liquid chromatography-electrospray tandem mass spectrometry (HPLC-ESI-MS/MS). K174 on the native peptide 171-IPAKTPPAPK-180 was identified to be acetylated ( Fig. 1a) , and this was confirmed with a synthetic peptide of the same sequence ( Fig. 1b) . To further characterize ac-K174 in AD brains, we generated a rabbit polyclonal antibody, AC312, with an antigen containing ac-K163 and ac-K174 (ac-K163 was included on the basis of previous in vitro studies 14, 15 ). Incubation of a 441-residue recombinant human tau (hTau, variant 2N4R) with the acetyltransferase p300 led to strong AC312-positive signals in western blot analyses, which were nondetectable without p300 ( Fig. 1c) . A pan-tau antibody Ab707 (ref. 14) detected comparable levels of tau with or without p300, suggesting that AC312 is specific for ac-tau. To determine the specificity of AC312 for different ac-K residues in tau, we transfected human embryonic kidney (HEK293) cells with wild-type (WT) or non-acetylatable mutant (KR) human tau (hTau) constructs with or without p300 coexpression. AC312 detected a strong p300-induced ac-tau signal in cells expressing WT hTau and various KR mutants except for K174R, indicating that AC312 is specific for ac-K174, although the peptide antigen contains ac-K163 ( Fig. 1d) .
We next assessed K174 acetylation in AD brains at different Braak stages ( Supplementary Table 1 ). Braak staging is a well-established method that correlates cortical tau pathology progression with the worsening of clinical symptoms 3 . Human brain lysates were partially purified on a column with an antibody to tau (tau-5) to reduce nonspecific signal. Immunoblot analysis with the tau-5 antibody showed similar concentrations of tau in each sample (Fig. 1e) . In contrast, AC312 immunoreactivity was weak or nondetectable in brain lysates at Braak stage 0 and stronger in lysates at early (stages 1-2) and later (3-5) Braak stages ( Fig. 1e,f) . Phosphorylated tau (p-tau) positive for PHF-1, which recognizes p-tau at S396 and S404, was more readily detected at later Braak stages. These findings suggest ac-K174 is among the early pathogenic alterations of tau in AD.
We examined AC312 immunoreactivity in PS19 transgenic mice, which express hTau with the P301S mutation under the mouse prion promoter and develop cognitive and synaptic deficits related to hippocampal function 19 . The specificity of AC312 immunoreactivity was confirmed in nontransgenic (Mapt +/+ ) and tau-deficient (Mapt −/− ) mice ( Supplementary Fig. 1a ). In PS19 mice at age 6 months, when early pathological changes start to appear 19 , pathological hTau was detected with MC1, an antibody specific for a pathogenic conformation of tau that precedes formation of tangles 20, 21 . AC312 and MC1 immunoreactivity was colocalized along the mossy fiber of the hippocampus (Fig. 1g-j and Supplementary Fig. 1b ).
K174Q slows tau turnover and promotes accumulation
Augmentation of tau acetylation via SIRT1 inhibition slows tau degradation in cultured neurons in vitro 14 . To determine whether ac-K174 is important in slowing tau turnover, we replaced K174 with glutamine (K174Q), which neutralizes the positive charge and mimics the acetylated state. We used a K174R mutant to mimic deacetylated tau. Both mutants are commonly used to assess the effects of acetylation [22] [23] [24] . To measure tau half-life, we infected rat primary neurons with lentiviral vectors expressing WT, K174Q or K174R hTau, and quantified hTau levels in the presence of the translation inhibitor cycloheximide. K174Q hTau had a longer half-life than K174R or WT hTau ( Fig. 2a) npg both K174Q and K174R, acetylation of K174, not blockage of polyubiquitation alone, seems to slow tau degradation. We next determined the effects of ac-K174 on tau accumulation in vivo by injecting adeno-associated virus type 1 (AAV1) vectors expressing WT (AAV-WT), K174Q (AAV-K174Q) and K174R (AAV-K174R) hTau constructs into the hippocampi of 2-to 3-month-old non-transgenic (NTG) C57BL/6 mice. Tau overexpression is known to induce toxicity in the hippocampus, which can be reliably targeted with AAV1 vectors. We compared K174Q to WT and K174R. Immunostaining with an anti-hTau antibody, HT7, showed similar distributions of hTau throughout the hippocampus 10 d after injection for all three constructs ( Fig. 2b,d) . Similar levels of hTau transduction were maintained 3 months after injection for all three constructs, as determined by quantitative reverse-transcription PCR (qRT-PCR) ( Fig. 2c,e ). However, western blot analysis of hippocampal lysates revealed that concentrations of monomeric K174Q tau were higher than those of WT ( Fig. 2f ,g) or K174R tau ( Fig. 2h,i) . In agreement with the effects of acetylation on the half-life of tau in vitro, these results indicate that ac-K174 acetylation, not the blockage of polyubiquitination, leads to monomeric tau accumulation in vivo. In addition, AAV-K174Q expression led to a marked increase in tau signal at ~140 kD, which is probably dimeric tau ( Fig. 2f,g and Supplementary  Fig. 2) . Notably, infection with AAV-K174R tau led to an increase of tau dimers similar to that seen with AAV-K174Q ( Fig. 2h,i) , supporting the importance of K174, but not its acetylation, in tau aggregation. Indeed, recombinant K174Q and K174R tau showed a higher propensity for aggregation than WT tau in vitro, as indicated by the time-dependent increase of thioflavin T signal, which identifies tau aggregates with β-sheet structures ( Fig. 2j) .
Acetylation of the KXGS motif suppresses tau phosphorylation at S262 and S356 (p-S262/S356) of KIGS 18 . K174Q expression via AAV infection in hippocampus did not significantly affect acetylation of KIGS motif (Supplementary Fig. 3 ) or levels of p-S262/S356 (unpaired Student's t-test) ( Supplementary Fig. 4a,b) . Levels of other p-tau species, including p-T231, p-T181 or p-S396 were also not significantly affected by K174Q expression ( Supplementary  Fig. 4c-e ). Notably, K174Q expression led to higher levels of AT8-positive p-tau (S202/T205) than did WT or K174R tau expression in hippocampus ( Supplementary Fig. 4f -i).
K174Q tau worsens neurodegeneration and behavioral deficits
To determine how ac-K174 affects toxicity of overexpressed hTau, we examined mouse hippocampal volumes 3 months after injection of AAV-WT, AAV-K174Q and AAV-K174R hTau. As reported previously, AAV-induced expression of WT hTau led to a loss of hippocampal volume 25 . K174Q hTau induced more severe hippocampal atrophy than did WT and K174R hTau ( Fig. 3a,b ), suggesting that ac-K174 induces more severe neurodegeneration.
To assess the functional outcome of high levels of ac-K174 in the hippocampus, we first used an open-field assay, as hippocampal lesions induce hyperlocomotion 26 . Additionally, we used the small Y-maze spontaneous-alternation task to evaluate hippocampal-dependent spatial working memory and the Morris water maze (MWM) to assess spatial learning and memory, which are known to be impaired in tauopathy mouse models 27 .
In the open-field test, mice injected with AAV-K174Q showed significantly higher total activity than noninjected (NI) mice, whereas mice expressing comparable levels of WT or K174R hTau behaved similarly to NI mice ( Fig. 3c) . Notably, the levels of K174Q tau monomers were positively correlated with total activity in the open field ( Fig. 3d) . In small Y-maze tests, hippocampal expression of K174Q but not WT or K174R hTau significantly reduced the percentage of spontaneous alternations ( Fig. 3e ), suggesting that ac-K174 tau impairs spatial working memory. In MWM tests, mice expressing K174Q hTau learned more slowly than NI mice and mice expressing WT and K174R hTau in the first phase of spatial learning ( Fig. 3f,h) . After all groups were trained to criterion, we performed reversal training by moving the hidden platform to a new location. Mice expressing K174Q took longer to find the platform in its new location than did NI controls and mice expressing WT or K174R hTau ( Fig. 3f,h) . These findings demonstrate that ac-K174 impairs spatial learning. In probe trials, in which the platform is removed from the MWM to measure memory retention, mice expressing K174Q hTau but not WT hTau crossed the target platform location significantly fewer times than did NI control mice, suggesting that K174Q expression impairs memory retention ( Fig. 3g) . A direct comparison of the effects of K174R and K174Q expression on memory retention was inconclusive, as the NI mice in this cohort showed no clear memory retention ( Fig. 3i) .
Inhibiting p300 reduces ac-K174 and total tau
The main acetyltransferases responsible for tau acetylation are p300 and its close homolog CBP 14, 15 . To further examine the role of p300, we deleted its encoding gene Ep300 by infecting primary mouse neurons expressing loxP-flanked Ep300 (p300 F/F ) with lentivirus expressing Cre recombinase in culture ( Fig. 4a) . Deletion of p300 lowered levels of total tau (t-tau), ac-K174 and p-tau (S202/T205) ( Fig. 4b) . Levels (relative to t-tau) of ac-K174 and AT8-positive p-tau were also reduced by p300 deletion (Fig. 4c) . Pharmacological inhibition of p300 with C646 reduces levels of p-tau and ac-tau in primary neurons 14 ; however, owing to its poor brain permeability and pharmacokinetic (PK) properties (data not shown), we tested other small molecules that inhibit p300, including salicylate, a nonsteroidal anti-inflammatory drugs (NSAIDs) (K.S. and E.V., unpublished data). In HEK293 cells, salicylate reduced acetylation of histone H2A at K5 (H2AK5), a well-established substrate of p300, in a dose-dependent manner (Supplementary Fig. 5a ). In rat primary neurons infected with a lentiviral vector carrying WT hTau (lenti-WT), salicylate reduced levels of p300 ( Fig. 4d) . Levels of ac-K174 ( Fig. 4d ) and AT8-positive p-tau ( Fig. 4d) were also reduced, relative to t-tau levels, by salicylate treatment. Consistent with the idea that ac-K174 inhibits tau degradation, reduction of ac-K174 with salicylate enhanced tau turnover in primary neurons (Supplementary Fig. 5b) .
To examine the potential protective effects of p300 inhibition against tauopathy in vivo, we first sought to determine whether p300 is aberrantly activated in the brains of PS19 mice. H3K18 acetylation has been used as an activity marker for p300 and its close homolog, CREB-binding protein (CBP), as deletion of p300 and CBP leads to a complete loss of ac-H3K18 (refs. [28] [29] [30] . Levels of ac-H3K18 in the brain were significantly higher in PS19 mice than in age-matched nontransgenic (NTG) controls (Fig. 4e) . To inhibit p300 and CBP in the brain, we treated PS19 mice with salsalate (SSA), a prodrug of salicylate used to treat rheumatoid arthritis. The results of PK analysis showed that, upon absorption, SSA penetrates the brain and gives rise to relatively stable salicylate levels over 8 h (Supplementary Fig. 6) .
We investigated the effects of SSA treatment in PS19 mice after the onset of tau-mediated deficits in spatial memory. We tested two independent cohorts: one cohort of 8-to 9-month-old female PS19 mice and NTG controls and one of 7-to 8-month-old male PS19 mice and NTG controls. The male and female mice were tested separately to avoid confounding effects of sex hormones on the other gender in behavior tests. Mice were given SSA (225 mg per kg of body weight (mg/kg)) or vehicle by oral gavage. The length of the treatment was 60 d for the female cohort and 84 d for the male cohort.
The dose of 225 mg/kg was well tolerated; no weight difference was observed in vehicle-and SSA-treated PS19 mice during treatment (data not shown). Inhibition of brain p300 was assessed by measurement of acetylation of well-established substrates for p300 and CBP [29] [30] [31] , including ac-H3K18, ac-H2AK5 and ac-H2BK12K15, all of which were reduced significantly by SSA treatment (Fig. 4f-h) . These results demonstrated clear target engagement of SSA in the brain when administered at 225 mg/kg. SSA treatment also reduced the levels of t-tau, as quantified with ELISA, but did not affect levels of tau mRNA (Fig. 4i) . SSA did not affect acetylation or phosphorylation of the KXGS motif ( Supplementary Fig. 7) , consistent with a lack of effect induced by K174Q. Notably, SSA induced a reduction in ac-K174 relative to t-tau and a trend of reduction in AT8-positive p-tau, which did not reach significance when normalized to t-tau ( Fig. 4j) .
SSA ameliorates pathology and memory deficits in PS19 mice
We next determined whether inhibition of ac-K174 tau ameliorates tau-mediated pathological and behavioral deficits. PS19 mice show hippocampal atrophy at advanced ages 32 . In the female cohort, hippocampal volume was similar in PS19 and NTG controls mice at age 8 months (Fig. 5a,b) . At 10 months of age, vehicle-treated PS19 mice showed significant hippocampal atrophy, as compared to NTG controls; SSA treatment restored hippocampal volumes of 10-month-old PS19 mice to those of 8-month-old NTG and PS19 mice (Fig. 5a,b) . Similarly, male SSA-treated PS19 mice also showed significantly (P = 0.0038) less hippocampal atrophy at 10 months of age ( Supplementary Fig. 8a,b) . Prominent NFTs and dystrophic neuritis, positive for Gallyas silver staining, were detected throughout the forebrains in PS19 mice (Fig. 5c) . SSA reduced the number of Gallyas silver-positive neurons and neurites in the cortex and hippocampus of PS19 mice, in both the female (Fig. 5c,d) , and the male cohorts ( Supplementary Fig. 8c,d) .
To assess SSA's effects on tau-mediated deficits in spatial learning and memory, we used the MWM or a fixed-location dry maze, a modified Barnes maze that measures spatial learning and memory but is less physically demanding than the MWM 33 . The male cohort was tested in the MWM. The female cohort was tested in the dry maze, as female mice were slightly older and appeared physically weaker than those in the male cohort. Mice in the fixed-location dry maze learned to locate the escape hole using spatial cues in the spatial learning segment. We observed no significant differences in learning rates among vehicle-treated NTG mice and vehicle-or SSA-treated PS19 mice (Fig. 5e) . In the probe trial, vehicle-treated NTG mice spent more time in the target quadrant than in the non-target quadrant, whereas vehicle-treated PS19 mice had no preference for the target quadrant, showing impaired memory retention and retrieval (Fig. 5f) . SSA-treated PS19 mice spent more time in the target quadrant, showing improved spatial memory. Similarly, in the MWM, no spatial learning deficits were observed in the four groups (Fig. 5g) . In the probe trial, vehicle-treated PS19 mice had no preference for the target quadrant (Fig. 5h) . In contrast, SSA-treated PS19 mice showed preferences for the target quadrant similar to that of vehicle-or SSA-treated NTG mice, confirming SSA's protective effects against tau-mediated memory impairment.
Ac-K174 inhibition mediates effects of salicylate or SSA
To investigate the mechanism underlying the effects of salicylate on tau, we examined primary rat neurons infected with AAV-WT or AAV-K174Q hTau and treated with salicylate. In neurons expressing WT (Fig. 6a,b ) or K174Q hTau ( Fig. 6d,e ), levels of p300 and mouse t-tau were similarly reduced, suggesting that salicylate induced a similar extent of p300 inhibition. However, although salicylate lowered levels of WT hTau (Fig. 6c) , it did not reduce those of K174Q hTau (Fig. 6f) , suggesting that salicylate's tau-lowering effect requires inhibition of ac-K174 in primary neurons.
We next determined whether SSA's beneficial effects involve inhibition of ac-K174 in vivo. NTG C57BL/6 mice were injected with AAV-K174Q; beginning two months after injection, mice were treated daily with SSA for one month. Ac-H2AK5 levels were reduced in the SSA-treated group compared to vehicle-treated controls, confirming SSA's inhibitory effect on p300 (Fig. 6g) . However, in contrast to our results in PS19 mice, SSA treatment failed to reduce levels of t-tau in AAV-K174Q-injected mice, as compared to vehicle-treated controls (Fig. 6h) . Levels of PHF-1-positive p-tau relative to t-tau or of AT8-positive p-tau normalized to that of t-tau or GAPDH, were also not affected by SSA treatment (Fig. 6i) . Moreover, SSA did not prevent or reduce hippocampal atrophy in AAV-K174Q-injected mice (Fig. 6j) , supporting the importance of ac-K174 inhibition in SSA's protective effects. 
DISCUSSION
Here we report a critical role for ac-K174, an early pathological modification of soluble tau in AD brains, in tau accumulation and toxicity. The acetyl-mimic tau mutant K174Q degrades more slowly than WT tau or K174R tau, which mimics the non-acetylatable form. Hippocampal expression of K174Q, but not WT or K174R tau, leads to accumulation of tau monomers that are associated with profound cognitive deficits related to AD. SSA inhibits p300, lowers ac-K174 levels in the brain and protects against behavioral deficits, hippocampal atrophy and accumulation of NFTs in aged PS19 mice. The tau-lowering and protective effects of salicylate and SSA were diminished in neurons and mice expressing K174Q tau. Our findings point to inhibitors of tau acetylation as a novel therapeutic modality to treat tauopathies.
Levels of ac-K174 were elevated at early Braak stages in AD brains, consistent with its role in early pathogenic alteration. In PS19 mice, ac-K174 colocalized with MC1, which is enriched in soluble tau in AD lysates and represents one of the earliest pathological tau conformations 20, 21 . In addition to K174, other tau acetylation sites have been reported, including K274, K280 and K259, K290, K321 and K353 (KXGS motifs) 15, 18, [34] [35] [36] . Both ac-K274 and ac-K280 have been found to be specifically associated with insoluble, thioflavin-positive tau aggregates in AD and other tauopathies [34] [35] [36] . Although ac-K280 has been implicated in deficient tau-microtubule interactions and pathological tau aggregation in vitro 15 , its pathogenicity in vivo has not been established. Acetylation of the KIGS motif, which appears to be reduced in AD brains, suppresses tau aggregation and promotes microtubule binding in vitro 18 . However, we show here that ac-K174 has few effects on acetylation or phosphorylation of KXGS motifs, suggesting that different tau acetylation sites may exert distinct effects on tau pathogenecity.
Our findings establish the pathogenicity of ac-tau in vivo. Behavioral deficits, including hyperactivity and impairments in working memory and spatial learning, were observed in mice expressing K174Q tau, but not in mice expressing WT or K174R tau at similar levels. The positive correlation of cognitive deficits with monomeric K174Q tau levels provides evidence supporting the pathogenicity of ac-K174 monomers. Tau-mediated neurodegeneration is exacerbated by ac-K174, but hippocampal atrophy is not abolished in mice expressing K174R, indicating that other mechanisms could be involved. Indeed, K174Q and K174R mutants enhance the formation of dimeric tau, which could be neurotoxic. Aberrant cell-cycle reentry induced by high levels of hTau 25 could also contribute to neurodegeneration in mice injected with AAV-K174Q or AAV-K174R. Our results also support a role of ac-K174 in tau homeostasis. Expression of K174Q, but not K174R, leads to longer half-life in primary neurons and aberrant accumulation in vivo, showing that ac-K174 acetylation, not the blockage of K174 polyubiquitination, impairs tau clearance. Notably, a recent mass-spectrometry study provided clear evidence that acetylation and ubiquitination occur on the same lysine residues, suggesting a close relationship between these two modifications 37 .
One of the main enzymes that acetylates tau is p300 (ref. 14) , which can be inhibited by salicylate or SSA, an ancient drug commonly used as an NSAID. Pharmacokinetically, SSA is quickly metabolized into its active component, salicylate. Unlike salicylate, aspirin (acetylsalicylate) leads to higher levels of ac-tau in cultured neurons (data not shown). SSA and aspirin have been widely used to treat rheumatoid arthritis and related illnesses in the past decades, and work presumably via inhibition of cyclo-oxygenase (COX) 38 . Interestingly, patients taking NSAIDs, including salicylate and derivatives, have a reduced risk of AD 39 . However, later trials with more specific COX-2 inhibitors did not establish a protective effect against AD. One possible explanation is that the benefits of salicylate might involve mechanisms independent of COX-2 inhibition, such as partial attenuation of p300 activity, which was identified recently as one of npg the most prominently dysregulated networks in AD brains in a system proteomic study 40 .
The resistance of K174Q to the tau-lowering and protective effects of salicylate and SSA strongly supports inhibition of ac-K174 as a key underlying mechanism. Treatment with salicylate lowered levels of ac-tau and t-tau in primary neurons expressing WT tau, but not in those expressing K174Q tau. SSA lowered ac-K174 and t-tau and protected against hippocampal atrophy in PS19 mice but failed to reduce tau or restore hippocampal volume in AAV-K174Q-injected mice. Other mechanisms are likely to be involved as well. For example, salicylate or SSA may exert protection by enhancing autophagy via activation of adenosine monophosphate-activated protein kinase (AMPK) 41 . The marked reduction of NFTs induced by SSA could be due to activation of autophagy. However, we did not observe significant difference in autophagy activity, as measured by abundance of LC3-II, in brains from PS19 mice treated with SSA or vehicle (Supplementary Fig. 9 ). More comprehensive analyses are needed to fully address the involvement of autophagy. SSA-induced AMPK activation could also lead indirectly to p300 inhibition and degradation 42, 43 . p300 is critical for nuclear factor-κB activation and glial inflammatory responses 44, 45 . We examined microgliosis or astrogliosis and observed no effect from SSA treatment, which suggests that anti-inflammation is not one of the main protective mechanisms (Supplementary Fig. 10) .
Our study provides proof-of-principle evidence that partial p300 inhibition could be used to treat tauopathies. Because p300 is important for many biological functions, completely inhibiting it could cause serious side effects. However, a recent study showed that p300 activity is aberrantly high in AD brains 40 . Identified as one of the most prominently dysregulated pathways in AD, aberrantly activated p300 could underlie hyperacetylation of tau in tauopathies 40 . In cases of moderate and severe AD, p300 activity has been found to be significantly higher than in non-demented controls in the CA1 region of the hippocampus, where activated p300 and p-tau are colocalized 40 . p300 activity was also elevated in aged PS19 brains. Thus, partial inhibition of p300 could normalize its aberrant activation and suppress hyperacetylation of its substrates, including tau. Indeed, the protection of SSA against tau-mediated cognitive deficits could have important clinical implications. Even after disease onset in PS19 mice, SSA treatment improved spatial memory, reduced NFT formation and abolished hippocampal atrophy, which is associated with increased risk for conversion from mild cognitive impairment to AD [46] [47] [48] . Notably, the dosage (225 mg/kg) used in our study is equivalent to ~1,350 mg per day for a 75-kg person 49 , lower than the dose typically prescribed (3,000 mg per day). Our study supports clinical evaluation of SSA and its derivatives as therapies in human tauopathies.
METHODS
Methods and any associated references are available in the online version of the paper. The average value of three replicates of each sample was expressed as the threshold cycle (C t ), at which the fluorescence signal starts to increase rapidly. Then, the difference (∆C t ) between the C t value for h-tau and the C t value for mouse GAPDH (∆C t = C t (human tau) -C t (GAPDH)) was calculated for each sample. The relative levels of gene expression for each sample was determined by 2 −∆ C t and expressed as fold change. The following primers were used for quantitative RT-PCR: h-tau (forward, 5′-GTTGGGGGACAGGAAAGATCAG-3′; reverse, 5′-CCGGGAGCTCCCTCATC-3′), mouse GAPDH (forward, 5′-GGGA AGCCCATCACCATCTT-3′; reverse, 5′-GCCTTCTCCATGGTGGTGAA-3′).
In vitro tau aggregation assay. Site-directed mutagenesis was used to generate K174Q and K174R mutants of the 0N4R tau isoform in a pET28a vector. WT and mutant proteins were expressed in Escherichia coli and purified by heat denaturation followed by cation exchange chromatography 55 . For aggregation assays, tau proteins (10 µM) were incubated in assay buffer: D-PBS, pH 7.2 (Invitrogen), 2 mM MgCl 2 , 1 mM DTT. Heparin (Santa Cruz, MW 6,000-25,000) was reconstituted in assay buffer then added at a final concentration of 44 µg/ml to induce tau aggregation. The aggregation assay was carried out at 37 °C with agitation. When monitoring aggregation kinetics, thioflavin T (ThT, Sigma) was dissolved in assay buffer and included in the reaction at a final concentration of 10 µM. The thioflavin T fluorescence intensity was measured in a Spectramax M5 reader (Molecular Devices) set to 444 nm/485 nm (excitation/emission) with an emission cutoff of 480 nm. Samples were read in a 384-well plate format, in quadruplicate, at 37 °C, with reads every 5 min and agitation between reads. Control reactions containing WT or mutant tau without heparin were included as baseline readings in each experiment. Baseline-subtracted kinetic data were fit to the Gompertz equation 56, 57 y Ae e t t i b
where y = the fluorescence at time t, A is the maximum signal/amplitude of curve, t i is the inflection point, t i -b = lag time, and b =1/k app where k app is the apparent elongation rate constant. Amplitude values are represented relative to WT controls for each experiment to adjust for day-to-day variations in absolute ThT signal intensity.
Mice. Mice were assigned into gender-and age-matched treatment groups in a randomized manner. The sample size for each experiment was determined on the basis of previous experience with each of the animal models used. For AAV-tau injection experiments, male (C57BL/6) mice at 2-3 months of age were purchased from the Jackson Laboratory and housed in a pathogen-free barrier facility at the University of California, San Francisco (UCSF) with a 12-h light/12-h dark cycle and ad libitum access to food and water. All behavior experiments were performed during daylight hours. All animal procedures were carried out under UCSF Institutional Animal Care and Use Committeeapproved guidelines. For SSA treatment experiments, female (first cohort) and male (second cohort) PS19 mice were purchased from the Jackson Laboratory. The mice were housed in a conventional facility at Stanford University with a reverse 12-h light/12-h dark cycle and ad libitum access to food and water.
All behavior experiments with PS19 mice were performed during daylight hours and carried out under Stanford University School of Medicine Institutional Animal Care and Use Committee-approved guidelines.
Stereotaxic injections.
Mice were anesthetized with avertin (250 mg/kg) by intraperitoneal injection, and secured on a stereotaxic frame (Kopf Instruments). Equal amount (~3 × 10 9 genomic particles) of AAV1 expressing tau WT, tau K174Q and tauK174R mutant were injected into dentate gyrus of 3-month-old mice by stereotaxic injection at a rate of 0.5 µl/min. The following coordinates were used (anterior-posterior -2.1, medial-lateral ±1.7, dorsal-ventral -2.1).
Oral gavage. Oral gavage was performed either at the animal facility at Stanford University (for PS19 mice) or at Preclinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center (for AAV-injected WT mice). Each group was assigned a different treatment in a semi-random manner. The investigators who performed the dosing and behavioral tests were blinded to the genotypes of the mice and to which vectors were injected. In the first PS19 cohort, two groups of 8-to 9-month-old PS19 female mice and one group of NTG littermate controls were used. PS19 female mice were given vehicle (PEG400/Tween 20 (4:1)) or SSA (225 mg/kg body weight) daily via single oral gavage ingestion (100 µl solution per 10 g body weight). NTG littermates were administered vehicle. Dosing was administered for 5 weeks before the initiation of the behavioral tests, and continued until the mice were sacrificed (60 d in total). In the repeat cohort, two groups (vehicle-and SSA-treated) of 7-to 8-month-old PS19 male mice and two groups (vehicle and SSA) of NTG littermate controls were used. The vehicle used in cohort 2 contained PEG-400 (10%, v/v), Tween-80 (10%, v/v), Labrasol (10%, v/v), hydroxypropyl β-cyclodextrin (20%, w/v), sodium phosphate (mono-basic), sodium phosphate (dibasic) and sodium chloride. Dosing was administered for about 60 d before the initiation of the MWM test and continued until the mice were sacrificed (86 d in total). Body weights of animals were monitored once a week. In the AAV-K174Qinjected cohort, 3-month-old C57BL/6 mice were injected with AAV-K174Q tau. Two months after injection, mice were treated daily with either vehicle or SSA (225 mg/kg body weight) for 6 weeks until sacrificed.
Hippocampal volume quantification and immunostaining and Gallyas silver staining. Investigators were blinded to the genotypes or treatment of the mice. For quantification of hippocampal volume, mice hemibrains were cut at 30 µm coronally, and all hippocampi, including sections, were collected. Brain sections were mounted on microscope slides (Fisher Scientific) in an anteriorto-posterior order, starting from the section where the hippocampal structure first becomes visible (first section) to the section where hippocampal structure just disappears (last section). Mice with missing sections were excluded from the analyses, a pre-established criterion. Mounted brain sections were dried at room temperature for 24 h and stained with cresyl violet (Nissl staining). After being defatted for 15 min in 100% xylene and 10 min in 100% ethanol then rehydrated, sections were stained in 0.1% cresyl violet solution and mounted in DePeX mounting medium (VWR). Images were acquired with a Keyence BZ-9000 microscope. Hippocampal volume was estimated using ImageJ (NIH) Volumest plugin (http://lepo.it.da.ut.ee/~markkom/volumest/). 10-12 hippocampalcontaining sections were typically used for each analysis. For immunostaining, floating sections were permeabilized and incubated in blocking solution (10% NGS in 0.3% Triton X-100 TBST) at room temperature for 1 h. After incubation with anti-HT7 (MN1000, Thermo Scientific), immunoreactive structures were detected with either Alexa Fluor 488-or Alexa Fluor 555-conjugated secondary antibodies (Invitrogen). For AC312 immunostaining, to reduce the nonspecific nuclear staining, the antibody was pre-absorbed by acetone Tau-knockout (KO) mice brain powder. Antigen retrieval was first performed by heating the sections in 10 mM citric acid at 90 °C for 30 min. Sections were then incubated with brain powder pre-absorbed AC312 and AT8 (Fisher) or MC1. After overnight incubation, the sections were incubated with secondary antibodies including Cy3-labeled donkey anti-rabbit IgG (Jackson ImmunoResearch) and fluorescein-labeled goat anti-mouse IgG (Vector Laboratories). All images were acquired by DM5000B microscope (Leica) or CSU-W1 spinning disk confocal microscope (Nikon) with 60× oil immersion objective lens and analyzed by either Micro-Manager software (UCSF) or ImageJ (NIH). For orthogonal images, images were collected as Z stacks with size of Z step as 0.15-µm and total 2.5-µm stacked images were rendered for orthogonal view with ImageJ. Gallyas silver staining was performed as described 58 . Briefly, sections were placed in 5% periodic acid followed by alkaline silver iodide solution and developer solution. After washing with acetic acid and water, they were placed in 0.1% gold chloride, followed by sodium thiosulphate solution, washed and counterstained in 0.1% nuclear fast red. For quantification, three sections were analyzed by bright light digital microscopy with an Olympus BX41 microscopy. Four fields per section and brain region were analyzed at 400× magnification, and silver-positive neuronal cell bodies and neurites were estimated and averaged per 0.1 mm 2 .
PK analyses of SSA and salicylate (SS) in brain and plasma. SSA was administered to C57BL/6 mice (males and females) via oral garage as a single bolus dose. Mice were sacrificed at predetermined time points and plasma and brain tissue samples were harvested for analysis by PPL labs (Redwood City, CA). SSA and its metabolite SA were measured simultaneously using oxopropanoyloxy npg
